Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects.
about
Neuroplasticity and the next wave of antidepressant strategiesAnti-inflammatory, antiapoptotic, and antioxidant activity of fluoxetinePremenstrual Dysphoric Disorder: Epidemiology and Treatment.Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice.Potential molecular and cellular mechanism of psychotropic drugsThe wnt pathway in mood disordersEffect of prenatal administration of venlafaxine on postnatal development of rat offspringResveratrol Ameliorates the Anxiety- and Depression-Like Behavior of Subclinical Hypothyroidism Rat: Possible Involvement of the HPT Axis, HPA Axis, and Wnt/β-Catenin Pathway.Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication.Gene expression: biomarker of antidepressant therapy?Designing modulators of 5-hydroxytryptamine signaling to treat abuse disorders.Resveratrol ameliorates chronic unpredictable mild stress-induced depression-like behavior: involvement of the HPA axis, inflammatory markers, BDNF, and Wnt/β-catenin pathway in rats.Antidepressant-Like Effect of Lipid Extract of Channa striatus in Postpartum Model of Depression in Rats.Therapeutic role of long non-coding RNA TCONS_00019174 in depressive disorders is dependent on Wnt/β-catenin signaling pathway.Cognitive flexibility impairment and reduced frontal cortex BDNF expression in the ouabain model of mania.Region-specific regulation of 5-HT1B receptors in the rat brain by chronic venlafaxine treatment.The Role of Fluoxetine in Activating Wnt/β-Catenin Signaling and Repressing β-Amyloid Production in an Alzheimer Mouse Model.
P2860
Q21129480-5C22B4A3-CA5A-4995-8BF6-FD1DE167A563Q26738965-DA56018C-F82E-4DC4-9715-51525F3863D1Q26786009-A0CAF2EA-C45E-4F3A-AF12-B933C3B0FE29Q33709399-51C16BF3-9FAE-4906-8A8E-DBA8CA53CFA4Q34129880-9EB330B6-C952-44F4-89EB-FAFAA2825C7DQ36310513-3970E1A9-9AF6-4EC5-8139-372BC133B42CQ36361644-D7DB247C-3D99-4B95-96F4-BECAF4CB3B35Q36928240-32CB090E-A21E-4DEF-8302-3E8FF5D9B4D5Q38122158-E3B3AC57-FB07-4E01-8087-19FED128367FQ38154917-48DDBCD6-ADCC-480B-AD65-DD03C28E3F9DQ38248774-7C14C5E5-94D3-4DCC-947B-2285B590347EQ47094829-343F8A66-3B75-4E92-900A-EC51D7E9883BQ47556012-DE30D81B-86C4-42EB-A1ED-C3F081DE9765Q47610993-71CED5A5-907E-4286-8B81-27623A215219Q48692917-853E3517-FE43-4D81-B757-E8F8102D6F72Q51050862-61272454-564D-4C4A-A2F0-E2B70BD0C98CQ55246899-73E9B5B0-DE0F-476C-B16D-22230220F460
P2860
Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, β-catenin and antidepressant-like effects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Subchronic treatment with fluo ...... d antidepressant-like effects.
@en
type
label
Subchronic treatment with fluo ...... d antidepressant-like effects.
@en
prefLabel
Subchronic treatment with fluo ...... d antidepressant-like effects.
@en
P2860
P1476
Subchronic treatment with fluo ...... nd antidepressant-like effects
@en
P2860
P304
P356
10.1111/J.1476-5381.2011.01516.X
P407
P577
2012-02-01T00:00:00Z